Browse the world's most comprehensive database of hedge fund investor letters, sorted by recent quarter. Access primary source research from leading institutional managers.
Buyside Digest is not affiliated with, and does not endorse, Baird Chautauqua International Growth Fund. This analysis is provided for institutional research purposes only and is not investment advice.
Fund Returns
QTD+3.74%
YTD-0.41%
Annualized+8.96%
Positioning StanceCONSTRUCTIVE
Market CapLarge Cap
GeographyGlobal, Asia, Europe
Digest Analysis
Quick Take
"The Baird Chautauqua International Growth Fund returned +3.74% net of fees in Q3 2026, outperforming its MSCI ACWI ex-U.S. Index benchmark by 326 basis points. Stock selection in health care, software, and Greater China drove relative gains, while managers actively redeployed capital from AI infrastructure trims into durable quality compounders like Linde, Adyen, and Constellation Software."
Executive Summary
The Baird Chautauqua International Growth Fund seeks long-term capital appreciation by investing in high-quality international companies possessing durable competitive advantages, healthy margins, robust balance sheets, and consistent cash generation across full market cycles. In the third quarter of 2026, the fund gained +3.74% net of fees, outpacing the +0.48% return of the MSCI ACWI ex-U.S. Index. Relative outperformance was driven by strong security selection within health care, information technology, real estate, and industrials, with top individual contributors including Recruit Holdings, WuXi Biologics, and BeOne Medicines. Performance was partially dampened by the strategy's lack of direct energy exposure amid surging crude prices and detractors such as Brookfield Renewable, Fanuc, and Ryanair. Macroeconomic conditions remained volatile due to escalating Middle East conflict, renewed central bank tightening from the Federal Reserve, European Central Bank, and Bank of Japan, and elevated interest rates. Portfolio managers rebalanced holdings by trimming AI infrastructure and selected biotech names while initiating a new position in Linde and deploying capital into core compounders such as 3i Group, Adyen, AIA Group, Constellation Software, and Suzuki.
Unlock Full Institutional Analysis
Sign in or create a free account to unlock full commentary, extracted equity pitches, and direct outbound manager source links with your 3 quarterly credits.